(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2018 (18.10.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/191141 A1

(51) International Patent Classification:
A61K 31/454 (2006.01) *A61K 31/58* (2006.01)
A61K 31/573 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2018/026661

(22) International Filing Date:
09 April 2018 (09.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/485,164 13 April 2017 (13.04.2017) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and
(71) Applicant *(for US only)*: **YU, Margaret K.** [US/US]; 10990 Wilshire Blvd, Suite 300, Los Angeles, California 90024 (US).

(72) Inventors: **YU, Margaret K.**; 10990 Wilshire Blvd., Suite 300, Los Angeles, California 90024 (US). **SNYDER, Linda Anne**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US).

(74) Agent: **SHIRTZ, Joseph F.** et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2018/191141 A1

(54) Title: COMBINATION THERAPY FOR PROSTATE CANCER

(57) Abstract: Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.